Noveris Health Sciences Engages DS Market Solutions for Liquidity Services

Vancouver, British Columbia — April 22, 2026 — Leads & Copy — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) has entered into an advisory agreement with DS Market Solutions Inc. (DSMS) for liquidity and stability services, according to an announcement made April 22, 2026.

Under the agreement, DSMS will assist in entering orders, including bidding and offering, and will provide Noveris Health Sciences with information regarding trading patterns in its securities on the Canadian Securities Exchange (CSE), along with reports on services performed. The engagement becomes effective May 1, 2026, and continues on a month-to-month basis unless either party terminates it with 30 days' written notice.

DSMS will receive compensation of $10,000 per month, plus applicable taxes. The agreement does not include any performance factors, and DSMS will not receive shares or options as compensation. DSMS will not provide promotional or investor relations services for Noveris Health Sciences.

Noveris Health Sciences states that DSMS is an arm's length party, and to the company’s knowledge, neither DSMS nor its principals have any direct or indirect interest in the securities of the company.

DSMS, located at 1160 Walden Circle, Unit 6, Mississauga, Ontario, is an independent provider of equity trading advisory and liquidity services.

Noveris Health Sciences Inc. is a biotechnology company developing medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD).

Source: Noveris Health Sciences Inc.